Publication:
Strategies to Reduce Oxidative Stress in Glaucoma Patients.

dc.contributor.authorPinazo-Duran, Maria D
dc.contributor.authorShoaie-Nia, Kian
dc.contributor.authorZanon-Moreno, Vicente
dc.contributor.authorSanz-Gonzalez, Silva M
dc.contributor.authorDel Castillo, Javier Benitez
dc.contributor.authorGarcia-Medina, Jose J
dc.date.accessioned2023-01-25T09:48:28Z
dc.date.available2023-01-25T09:48:28Z
dc.date.issued2018
dc.description.abstractPrimary open-angle glaucoma (POAG) is a multifactorial pathology involving a variety of pathogenic mechanisms, including oxidative/nitrosative stress. This latter is the consequence of the imbalance between excessive formation and insufficient protection against reactive oxygen/nitrogen species. Our main goal is to gather molecular information to better managing pathologic variants that may determine the individual susceptibility to oxidative/nitrosative stress (OS/NS) and POAG. An extensive search of the scientific literature was conducted using PUBMED, the Web of Science, the Cochrane Library, and other references on the topic of POAG and OS/NS from human and animal model studies published between 2010 and 2017. Finally, 152 works containing relevant information that may help understanding the role of antioxidants, essential fatty acids, natural compounds and other similar strategies for counteracting OS/NS in POAG were considered. A wide variety of studies have proven that antioxidants, among them vitamins B3, C and E, Coenzyme Q10 or melatonin, ω-3/ω-6 fatty acids and other natural compounds (such as coffee, green tea, bear bile, gingko biloba, coleus, tropical fruits, etc.,) may help regulating the intraocular pressure as well as protecting the retinal neurons against OS/NS in POAG. Based on the impact of antioxidants and ω-3/ω-6 fatty acids at the molecular level in the glaucomatous anterior and posterior eye segments, further studies are needed by integrating all issues involved in glaucoma pathogenesis, endogenous and exogenous risk factors and their interactions that will allow us to reach newer effective biotherapies for preventing glaucomatous irreversible blindness.
dc.identifier.doi10.2174/1570159X15666170705101910
dc.identifier.essn1875-6190
dc.identifier.pmcPMC6120109
dc.identifier.pmid28677495
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6120109/pdf
dc.identifier.unpaywallURLhttps://europepmc.org/articles/pmc6120109?pdf=render
dc.identifier.urihttp://hdl.handle.net/10668/11375
dc.issue.number7
dc.journal.titleCurrent neuropharmacology
dc.journal.titleabbreviationCurr Neuropharmacol
dc.language.isoen
dc.organizationÁrea de Gestión Sanitaria de Jerez, Costa Noroeste y Sierra de Cádiz
dc.organizationAGS - Jerez, Costa Noroeste y Sierra de Cáidz
dc.page.number903-918
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectGlaucoma
dc.subjectantioxidants
dc.subjectessential fatty acids
dc.subjectnatural compounds
dc.subjectnitrosative stress
dc.subjectoxidative stress.
dc.subject.meshAnimals
dc.subject.meshAntioxidants
dc.subject.meshGlaucoma
dc.subject.meshHumans
dc.subject.meshOxidative Stress
dc.titleStrategies to Reduce Oxidative Stress in Glaucoma Patients.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number16
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
PMC6120109.pdf
Size:
1.32 MB
Format:
Adobe Portable Document Format